Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001.
Wiedermann U, Garner-Spitzer E, Chao Y, Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen CJ, Yau TC, Tanasanvimon S, Maneechavakajorn J, Sookprasert A, Bai LY, Chou WC, Ungtrakul T, Drinic M, Tobias J, Zielinski CC, Chong L, Ede NJ, Marino MT, Good AJ. Wiedermann U, et al. Among authors: zielinski cc. Clin Cancer Res. 2021 Jul 1;27(13):3649-3660. doi: 10.1158/1078-0432.CCR-20-3742. Epub 2021 Apr 20. Clin Cancer Res. 2021. PMID: 33879458 Clinical Trial.
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
Köstler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C, Zielinski CC. Köstler WJ, et al. Among authors: zielinski cc. Clin Cancer Res. 2004 Mar 1;10(5):1618-24. doi: 10.1158/1078-0432.ccr-0385-3. Clin Cancer Res. 2004. PMID: 15014012
Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.
Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H. Hafner C, et al. Among authors: zielinski cc. Int J Cancer. 2005 Apr 10;114(3):426-32. doi: 10.1002/ijc.20769. Int J Cancer. 2005. PMID: 15578703 Free article.
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Köstler WJ, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger GG, Singer CF, Attems J, Rabitsch W, Fakhrai N, Elandt K, Wiltschke C, Hejna M, Zielinski CC. Köstler WJ, et al. Among authors: zielinski cc. J Cancer Res Clin Oncol. 2005 Jul;131(7):420-8. doi: 10.1007/s00432-005-0670-3. Epub 2005 Apr 29. J Cancer Res Clin Oncol. 2005. PMID: 15864644
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ, Hudelist G, Rabitsch W, Czerwenka K, Müller R, Singer CF, Zielinski CC. Köstler WJ, et al. Among authors: zielinski cc. J Cancer Res Clin Oncol. 2006 Jan;132(1):9-18. doi: 10.1007/s00432-005-0038-8. Epub 2005 Sep 24. J Cancer Res Clin Oncol. 2006. PMID: 16184380
492 results